Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus Inc. has a patent license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases. The company is based in Columbia, Maryland.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-905-3197070
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$2.42 million
Profitability
Miscellaneous
Employees7
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable
Medifocus (CVE:MFS) Frequently Asked Questions
What is Medifocus' stock symbol?
Medifocus trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MFS."
When is Medifocus' next earnings date?
Has Medifocus been receiving favorable news coverage?
Media headlines about MFS stock have been trending somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Medifocus earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Medifocus.
Who are some of Medifocus' key competitors?
Some companies that are related to Medifocus include Revive Therapeutics (RVV), CAN-FITE BIOPHA/S (CANF), IBEX Technologies (IBT), Can-Fite Biopharma (CANF), Hemostemix (HEM), Hemispherx BioPharma (HEB), BPH Energy (BPH), Physiomics (PYC), ImmunoCellular Therapeutics (IMUC), SalvaRx Group (SALV), ValiRx (VAL), Cotinga Pharmaceuticals (COT), Pacgen Life Science (PBS), Port Erin Biopharma Investments (PEBI) and AngioSoma (SOAN).
What other stocks do shareholders of Medifocus own?
Who are Medifocus' key executives?
Medifocus' management team includes the folowing people:
- Dr. William W. Jow, CEO, Pres & Director (Age 61)
- Mr. Mirsad Jakubovic C.A., M.B.A., Chief Financial Officer (Age 57)
- Mr. John Mon, VP of Regulatory Affairs & Product Devel. (Age 66)
- Mr. Douglas Liu, VP of Fin. (Age 55)
- Dr. Stuart E. Katz M.D., VP of Operations
How do I buy shares of Medifocus?
Shares of MFS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How big of a company is Medifocus?
What is Medifocus' official website?
How can I contact Medifocus?
Medifocus' mailing address is The Exchange Tower Suite 1800, 130 King Street West, PO Box 427, TORONTO, ON M5X 1E3, Canada. The company can be reached via phone at +1-905-3197070.
MarketBeat Community Rating for Medifocus (CVE MFS)
MarketBeat's community ratings are surveys of what our community members think about Medifocus and other stocks. Vote "Outperform" if you believe MFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
